Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway

Journal of Bone and Mineral Research

Volumn 23, Issue 5, 2008, Pages 750-758

  Stein, Nicola C ^a,b   Kreutzmann, Carmen ^a   Zimmermann, Sara Pia ^a   Niebergall, Ute ^a   Hellmeyer, Lars ^a   Goettsch, Claudia ^b   Schoppet, Michael ^a   Hofbauer, Lorenz C ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Endothelial cells; Interleukin 4; Osteoporosis; Osteoprotegerin; STAT6

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; MESSENGER RNA; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHOLIPASE C INHIBITOR; STAT6 PROTEIN; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE;

ARTICLE; BONE DEVELOPMENT; BONE REMODELING; CELL ACTIVATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; GENE INDUCTION; HORMONE RELEASE; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REGULATORY MECHANISM; SUPERNATANT; TH2 CELL;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; OSTEOPROTEGERIN; RNA, MESSENGER; STAT6 TRANSCRIPTION FACTOR;

EID: 42449107355     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080203     Document Type: Article

References (40)

1. Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:1504-1508.
2. Kong YY, Boyle WJ, Penninger JM 2000 Osteoprotegerin ligand: A regulator of immune responses and bone physiology. Immunol Today 21:495-502.
3. Hofbauer LC, Schoppet M 2004 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Eliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
5. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
6. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527.
7. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R 2002 Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87:4470-4475.
8. Schoppet M, Preissner KT, Hofbauer LC 2002 RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549-553.
9. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
10. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS 2000 Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474.
11. Paul WE 1991 Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77:1859-1870.
12. Mangashetti LS, Khapli SM, Wani MR 2005 IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-κB and Ca2+ signaling. J Immunol 175:917-925.
13. Abu-Amer Y 2001 IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J Clin Invest 107:1375-1385.
14. Moreno JL, Kaczmarek M, Keegan AD, Tondravi M 2003 IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: Irreversible inhibition of the differentiation program activated by RANKL. J Immunol 102:1078-1086.
15. Wei S, Wang MW, Teitelbaum SL, Ross FP 2002 Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-κB and mitogen-activated protein kinasesignaling. J Biol Chem 277:6622-6630.
16. Palmqvist P, Lundberg P, Persson E, Johansson A, Lundgren I, Lie A, Conaway HH, Lerner UH 2006 Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem 281:2414-2429.
17. Hofbauer LC, Schrader J, Niebergall U, Viereck V, Burchert A, Hörsch D, Preissner KT, Schoppet M 2006 Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thromb Haemost 95:708-714.
18. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR 2005 Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204:714-723.
19. Finkelman FD, Shea-Donohue T, Morris SC, Gildea L, Strait R, Madden KB, Schopf L, Urban JF Jr 2004 Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 201:139-155.
20. Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards CD, Miossec P, van Den Berg WB 2000 IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 105:1697-1710.
21. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD 2003 Interleukin-4 and interleukin-13 signaling connections maps. Science 300:1527-1528.
22. Kotowicz K, Callard RE, Friedrich K, Matthews DJ, Klein N 1996 Biological activity of IL-4 and IL-13 on human endothelial cells: Functional evidence that both cytokines act through the same receptor. Int Immunol 8:1915-1925.
23. Keegan AD, Johnston JA, Tortolani PJ, McReynolds LJ, Kinzer C, O'Shea JJ, Paul WE 1995 Similarities and differences in signal transduction by interleukin 4 and interleukin 13: Analysis of Janus kinase activation. Proc Natl Acad Sci USA 92:7681-7685.
24. Palmer-Crocker RL, Hughes CC, Pober JS 1996 IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain. J Clin Invest 98:604-609.
25. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309.
26. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P 2001 Receptor activator of NF-κB and OPG expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276:20659-20672.
27. Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW 2001 IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 98:2443-2448.
28. Saidenberg-Kermanac'h N, Bessis N, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal M 2004 Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. J Clin Immunol 24:370-378.
29. Alayan J, Ivanovski S, Farah CS 2007 Alveolar bone loss in T helper 1/T helper 2 cytokine-deficient mice. J Periodontal Res 42:97-103.
30. Yao L, Pan J, Setiadi H, Patel KD, McEver RP 1996 Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. J Exp Med 184:81-92.
31. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P 1996 Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol 156:2558-2565.
32. Lee YW, Hennig B, Toborek M 2003 Redox-regulated mechanisms of IL-4-induced MCP-1 expression in human vascular endothelial cells. Am J Physiol Heart Circ Physiol 284:H185-H192.
33. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V 2004 Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246-4253.
34. Iribarren C, Sidney S, Sternfeld B, Browner WS 2000 Calcification of the aortic arch: Risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA 283:2810-2815.
35. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR 2005 Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 20:1912-1920.
36. George J, Mulkins M, Shaish A, Casey S, Schatzman R, Sigal E, Harats D 2000 Interleukin (IL)-4 deficiency does not influence fatty streak formation in C57BL/6 mice. Atherosclerosis 153:403-411.
37. King VL, Szilvassy SJ, Daugherty A 2002 Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/-mice. Arterioscler Thromb Vasc Biol 22:456-461.
38. Davenport P, Tipping PG 2003 The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 163:1117-1125.
39. 3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem 275:20959-20962.
40. Grehan JF, Levay-Young BK, Fogelson JL, Francois-Bongarcon V, Benson BA, Dalmasso AP 2005 IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway. J Immunol 175:1903-1910.